Search

Displaying results 4451 - 4460 of 10000 in total
  1. Drug

    Epicept NP-1

    go.drugbank.com/drugs/DB05492
    Investigational

    Peripheral neuropathies are medical conditions caused by damage to the nerves in the peripheral nervous system. … EpiCept NP-1 Cream is a patented formulation containing two FDA-approved drugs, amitriptyline (a widely-used antidepressant) and ketamine (an NMDA antagonist that is used as an anesthetic).

  2. Drug

    Limaprost

    go.drugbank.com/drugs/DB09211
    Investigational

    It also improves poor blood flow in the nerve tissue in cervical spondylosis and normalizes nerve function. … In 2011, Ono and DSP initiated Phase II clinical trials in Japan for the treatment of carpal tunnel syndrome. In 2013, these trials were discontinued because the study failed to demonstrate efficacy.

  3. Drug

    DDP-225

    go.drugbank.com/drugs/DB05642
    Investigational

    Dynogen licensed preclinical and clinical data related to DDP225 from Mitsubishi Pharma in October 2003. … Noradrenaline and serotonin are neurotransmitters that are known to be involved in the control of the gastrointestinal system.

  4. Drug

    Nifedipine

    go.drugbank.com/drugs/DB01115
    ApprovedInvestigational

    [A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972. … [A190273] The most popular of the third generation dihydropyridines is [amlodipine].[A190273] Nifedipine was granted FDA approval on 31 December 1981.[L11383]

  5. Drug

    Relacatib

    go.drugbank.com/drugs/DB06367
    Investigational

  6. Drug

    Oblimersen

    go.drugbank.com/drugs/DB13811
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    1,10-Phenanthroline

    go.drugbank.com/drugs/DB02365
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    LX6171

    go.drugbank.com/drugs/DB05180
    Investigational

    LX6171 is an oral drug candidate that was generated by Lexicon medicinal chemists and is being developed to treat disorders characterized by cognitive impairment, such as Alzheimer's disease, schizophrenia

  9. Drug

    PPI-1019

    go.drugbank.com/drugs/DB05832
    Investigational

    Apan (PPI-1019) is developed by Praecis Pharmaceuticals to treat Alzheimer's Disease.

  10. Drug

    NRP409

    go.drugbank.com/drugs/DB05235
    Experimental

    NRP409 is a triiodothyronine (T3) hormone, being investigated by New River Pharmaceuticals as a treatment for patients with primary hypothyroidism.